Fig. 5.

Serum anti-gp120 IgG in immunized animals that received HIV/SIV antigen-containing vaccine (groups 2, 3, and 4). (A) Median endpoint titers over time. The dashed line indicates the time of challenge. (B) Individual endpoint titers at the time of challenge. (C) Correlation between anti-gp120 IgG levels (log₁₀ titer) and neutralizing activity in the absence of complement (ID₅₀) at the time of challenge in groups 2 and 3. The protected animals (F42 and F44) are denoted with empty symbols.